[{"address1": "10 King Street East", "address2": "Suite 600", "city": "Toronto", "state": "ON", "zip": "M5C 1C3", "country": "Canada", "phone": "877-422-5242", "website": "https://www.medexus.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.", "fullTimeEmployees": 82, "companyOfficers": [{"maxAge": 1, "name": "Mr. Kenneth  d'Entremont", "title": "CEO & Director", "fiscalYear": 2024, "totalPay": 1039731, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard  Labelle", "title": "Chief Operating Officer", "fiscalYear": 2024, "totalPay": 345600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ian C. Wildgoose Brown", "title": "General Counsel & Corporate Secretary", "fiscalYear": 2024, "totalPay": 424693, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brendon  Buschman", "title": "Chief Financial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tina  Byers CFA", "title": "Executive of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bill  Poncy", "title": "Senior Vice President of Commercial Operations - United States", "fiscalYear": 2024, "totalPay": 439694, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian  Peters", "title": "Vice President of Sales & Marketing - United States", "fiscalYear": 2024, "totalPay": 294963, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 1.79, "open": 1.94, "dayLow": 1.94, "dayHigh": 2.0, "regularMarketPreviousClose": 1.79, "regularMarketOpen": 1.94, "regularMarketDayLow": 1.94, "regularMarketDayHigh": 2.0, "beta": 1.952, "trailingPE": 50.0, "forwardPE": 28.571428, "volume": 25855, "regularMarketVolume": 25855, "averageVolume": 15064, "averageVolume10days": 4650, "averageDailyVolume10Day": 4650, "bid": 1.97, "ask": 2.0, "bidSize": 40000, "askSize": 40000, "marketCap": 49356600, "fiftyTwoWeekLow": 1.06, "fiftyTwoWeekHigh": 2.562, "priceToSalesTrailing12Months": 0.45372027, "fiftyDayAverage": 1.6662, "twoHundredDayAverage": 1.43617, "currency": "USD", "enterpriseValue": 84807848, "profitMargins": 0.010039999, "floatShares": 22227987, "sharesOutstanding": 24525500, "heldPercentInsiders": 0.09197, "heldPercentInstitutions": 0.08389, "bookValue": 1.332, "priceToBook": 1.5015014, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": 2.006, "netIncomeToCommon": 1092000, "trailingEps": 0.04, "forwardEps": 0.07, "enterpriseToRevenue": 0.78, "enterpriseToEbitda": 4.749, "exchange": "OQX", "quoteType": "EQUITY", "symbol": "MEDXF", "underlyingSymbol": "MEDXF", "shortName": "Medexus Pharmaceuticals Inc", "longName": "Medexus Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1511793000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e3449c76-7991-31d7-b383-ed33532f2023", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.0, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 8454000, "totalCashPerShare": 0.345, "ebitda": 17858000, "totalDebt": 46835000, "quickRatio": 0.366, "currentRatio": 1.105, "totalRevenue": 108782000, "debtToEquity": 143.723, "revenuePerShare": 4.653, "returnOnAssets": 0.048850004, "returnOnEquity": 0.03948, "freeCashflow": 13506625, "operatingCashflow": 22692000, "earningsGrowth": 1.667, "revenueGrowth": -0.135, "grossMargins": 0.57573, "ebitdaMargins": 0.16416, "operatingMargins": 0.15871, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]